These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review]. Kieffer P; Hinschberger O; Ciobanu E; Jaeger-Bizet F; Drabo A; Mostoufizadeh T; Martzolff L Rev Med Interne; 2014 Jan; 35(1):56-9. PubMed ID: 24075627 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients]. Broner J; Arnaud E Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884 [TBL] [Abstract][Full Text] [Related]
7. Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment. Naderi N Clin Exp Rheumatol; 2020; 38 Suppl 124(2):207-209. PubMed ID: 32359040 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 blockade in refractory giant cell arteritis. Ly KH; Stirnemann J; Liozon E; Michel M; Fain O; Fauchais AL Joint Bone Spine; 2014 Jan; 81(1):76-8. PubMed ID: 23890680 [TBL] [Abstract][Full Text] [Related]
9. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Alten R; Maleitzke T Ann Med; 2013 Jun; 45(4):357-63. PubMed ID: 23650978 [TBL] [Abstract][Full Text] [Related]
10. PMR and GCA: steroids or bust. Adizie T; Dasgupta B Int J Clin Pract; 2012 Jun; 66(6):524-7. PubMed ID: 22607502 [No Abstract] [Full Text] [Related]
11. Tocilizumab (Actemra) for giant cell arteritis. Med Lett Drugs Ther; 2017 Sep; 59(1530):161-162. PubMed ID: 28922343 [No Abstract] [Full Text] [Related]
12. Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis. Berger CT; Recher M; Daikeler T Rheumatology (Oxford); 2018 Jan; 57(1):196-197. PubMed ID: 28968856 [No Abstract] [Full Text] [Related]
13. Giant cell arteritis: An updated review of an old disease. Rinden T; Miller E; Nasr R Cleve Clin J Med; 2019 Jul; 86(7):465-472. PubMed ID: 31291180 [TBL] [Abstract][Full Text] [Related]
14. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Schaufelberger C; Möllby H; Uddhammar A; Bratt J; Nordborg E Scand J Rheumatol; 2006; 35(4):327-9. PubMed ID: 16882602 [No Abstract] [Full Text] [Related]
15. Foreword: clinical challenges of diagnosing and managing giant cell arteritis. Stone JH Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii1-ii2. PubMed ID: 29982783 [No Abstract] [Full Text] [Related]
16. [Anti-IL-6 : new therapeutic trends]. Candil M; Zufferey P Rev Med Suisse; 2017 Jan; 13(544-545):105-109. PubMed ID: 28703549 [TBL] [Abstract][Full Text] [Related]
17. Infliximab as monotherapy in giant cell arteritis. Uthman I; Kanj N; Atweh S Clin Rheumatol; 2006 Feb; 25(1):109-10. PubMed ID: 15902519 [No Abstract] [Full Text] [Related]
18. [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?]. Samson M; Bonnotte B Rev Med Interne; 2018 Feb; 39(2):75-77. PubMed ID: 29217104 [No Abstract] [Full Text] [Related]
19. Tocilizumab, an interleukin-6 inhibitor: a steroid sparing agent in giant cell arteritis. Jobanputra P; Ford M J R Coll Physicians Edinb; 2017 Sep; 47(3):250-252. PubMed ID: 29465101 [No Abstract] [Full Text] [Related]
20. Immunosuppressive treatment for giant cell arteritis: where do we stand? Pipitone N; Salvarani C Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-5-6. PubMed ID: 26016749 [No Abstract] [Full Text] [Related] [Next] [New Search]